News | April 29, 2023
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Revenue from operations up 26% to Rs. 768 crores
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Subscribe To Our Newsletter & Stay Updated
